Jenny J. Kim

TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.

TL;DR: Long-term activity and safety outcomes of the ZUMA-1 study suggest that axicabtagene ciloleucel can induce durable responses and a median overall survival of greater than 2 years, and has a manageable relapsed or refractory disease or relapsed after autologous stem-cell transplantation.

TL;DR: Most patients benefited from tumor removal, except for those with four or more IMDC risk factors, and CN is beneficial in synchronous mRCC patients treated with targeted therapy, even after adjusting for prognostic factors.

TL;DR: These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patientsWith clear cell carcinoma after first- line treatment with another tyrosine kinase inhibitor.

TL;DR: Angiotensin system inhibitors may improve the outcome of sunitinib treatment in metastatic renal cell carcinoma and should be investigated prospectively, and if validated applied in clinical practise and clinical trials.